Tern Plc to exercise warrants in Wyld Networks

Tern - Wyld Networks

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, has announced that it has committed to exercise the 320,454 TO2 Warrants in Wyld Networks AB which represents all of the TO2 Warrants that were issued to Tern pursuant to its investment as part of Wyld Networks’ Offering in conjunction with Wyld Networks’ IPO and admission to trading on the NASDAQ First North Growth Market in Stockholm on 2 July 2021.

Tern will pay SEK 2,794,359 (approximately £220,000) to exercise its TO2 Warrants to subscribe for 320,454 shares in Wyld Networks at SEK 8.72 per share, and this will be funded from Tern’s existing cash resources.

Prior to the completion of the TO2 Warrant exercises Tern held 46.5% of Wyld Networks’ issued share capital. The subscription period for the in aggregate, 2,275,000 TO2 Warrants commenced on 6 December 2022 and will end on 19 December 2022. If all of the TO2 Warrants are exercised Tern’s holding in Wyld Networks will reduce to 41.0% and a further announcement regarding Tern’s resultant holding in Wyld Networks will be made when the exercise period for the TO2 Warrants is completed.

Capitalised terms not otherwise defined herein have the same meaning as in the Company’s announcement “Proposed IPO of Wyld Networks” made on 9 June 2021.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc updates position in Talking Medicines with new convertible loan notes

Tern Plc has received about £230,000 in new unsecured convertible loan notes from Talking Medicines after cancelling around £180,000 of short term loans provided over 2024 and 2025.

The real problem holding back connected vehicle programmes

Vehicle identity is fast becoming a core infrastructure challenge, and a new bottleneck for OEMs aiming to scale software-defined platforms.

Talking Medicines is building the AI layer beneath pharma marketing

Talking Medicines is shifting pharma marketing from content creation to data control, building the layer AI tools rely on to deliver credible, measurable clinical messaging.

A shift in how IoT is secured by default

KeyScaler 2025 transforms IoT security by automating trust across every device’s lifecycle, from onboarding to decommissioning, turning scalable connectivity and compliance into a built-in feature.

Turning employee sentiment into hard operational data

Workforce wellbeing is becoming a source of operational data, and the companies acting early are already reducing risk.

Tern Plc Extends Convertible Loan Maturities in Talking Medicines to Strengthen Exit Strategy

Tern Plc extends all convertible loan maturities in Talking Medicines to 2029, enhancing its strategic position for future exit.

Search

Search